Impfungen in der Pneumologie

C. Forstner; M. W. Pletz

doi:10.1055/s-0034-1377412

Pneumologie, Inhaltsverzeichnis

Pneumologie 2014; 68(10): 653-661
DOI: 10.1055/s-0034-1377412

Übersicht

Impfungen in der Pneumologie^[*]

Vaccinations in Pneumology

Autor*innen

C. Forstner

¹Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena

²Universitätsklinik für Innere Medizin I, Klinische Abteilung für Infektionskrankheiten und Tropenmedizin, Medizinische Universität Wien
M. W. Pletz

¹Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena

Abstract

Zusammenfassung

Die effektivste Maßnahme zur Prävention von Infektionen des Respirationstrakts ist der Einsatz von Schutzimpfungen gegen wichtige respiratorische Pathogene. Aufgrund ihrer großen klinischen Relevanz wird die Vakzinierung gegenüber Pneumokokken, Influenza A/B-Virus und Bordetella pertussis nicht nur im Kindesalter, sondern auch im Erwachsenenalter von der Ständigen Impfkommission am Robert Koch Institut empfohlen. In der vorliegenden Übersichtsarbeit werden die klinische Bedeutung und Sicherheit der entsprechenden Impfungen anhand der aktuellen Datenlage als auch die Vor- und Nachteile der unterschiedlichen verfügbaren Impfstoffe diskutiert.

Abstract

The best measure to prevent infections of the respiratory tract is the use of vaccines against important respiratory tract pathogens. The Standing Vaccination Committee at the Robert Koch Institute recommends not only children but also adult vaccination against pneumococci, influenza A/B and Bordetella pertussis, because of a high disease burden. In the present review the clinical significance and safety of those vaccinations as well as advantages and disadvantages of the currently available vaccines are discussed.

Volltext

Referenzen

Literatur
1 Robert Koch Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Epid Bull 2013; 34: 313-334
2 Lode H, Ludwig E, Kassianos G. Pneumococcal infection – low awareness as a potential barrier to vaccination: results of a European study. Adv Ther 2013; 30: 387-405
3 Beel ER, Rench MA, Montesinos DP et al. Acceptability of immunization in adult contacts of infants: Possibility of expanding platforms to increase adult vaccine uptake. Vaccine 2014; 32: 2540-2545
4 Lode H. Bacterial community-acquired pneumonia: risk factors for mortality and supportive therapies. Intensive Care Med 2009; 35: 391-393
5 Pletz MW, Rohde G, Schutte H et al. Epidemiology and Aetiology of Community-acquired Pneumonia (CAP). Dtsch Med Wochenschr 2011; 136: 775-780
6 Varon E, Mainardi JL, Gutmann L. Streptococcus pneumoniae: still a major pathogen. Clin Microbiol Infect 2010; 16: 401
7 Schmidt-Ioanas M, Lode H. Treatment of pneumonia in elderly patients. Expert Opin Pharmacother 2006; 7: 499-507
8 Aliberti S, Mantero M, Mirsaeidi M et al. The role of vaccination in preventing pneumococcal disease in adults. Clin Microbiol Infect 2014; 20 (Suppl. 05) 52-58
9 Forstner C, Plefka S, Tobudic S et al. Effectiveness and immunogenicity of pneumococcal vaccination in splenectomized and functionally asplenic patients. Vaccine 2012; 30: 5449-5452
10 Rose M, Lode H, de Roux A et al. Pneumococcal vaccination in obstructive lung diseases – what can we expect?. Dtsch Med Wochenschr 2005; 130: 461-465
11 Lee H, Kim J, Tagmazyan K. Treatment of stable chronic obstructive pulmonary disease: the GOLD guidelines. Am Fam Physician 2013; 88: 655-663 , 663B-F
12 Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4: 144-154
13 Rodrigo C, Lim WS. The relevance of pneumococcal serotypes. Curr Infect Dis Rep 2014; 16: 403
14 Johnson HL, Deloria-Knoll M, Levine OS et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010; 7: e1000348
15 Grabenstein JD, Weber DJ. Pneumococcal serotype diversity among adults in various countries, influenced by pediatric pneumococcal vaccination uptake. Clin Infect Dis 2014; 58: 854-864
16 Harboe ZB, Benfield TL, Valentiner-Branth P et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010; 50: 329-337
17 Pletz MW, Welte T, Klugman KP. The paradox in pneumococcal serotypes: highly invasive does not mean highly lethal. Eur Respir J 2010; 36: 712-713
18 de Roux A, Lode H. Pneumococcal vaccination. Eur Respir J 2005; 26: 982-983
19 Pletz MW, Maus U, Krug N et al. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 2008; 32: 199-206
20 de Roux A, Schmöle-Thoma B, Silber GR et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46: 1015-1023
21 Sigurdardottir ST, Center KJ, Davidsdottir K et al. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children. Vaccine 2014; 32: 417-424
22 Musher DM, Manoff SB, McFetridge RD et al. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin 2011; 7: 919-928
23 Moberley S, Holden J, Tatham DP et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1: CD000422
24 Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9: 213-220
25 Clutterbuck EA, Lazarus R, Yu LM et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect 2012; 205: 1408-1416
26 Lazarus R, Clutterbuck E, Yu LM et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 2011; 52: 736-742
27 Weil Olivier C. Ten years of experience with the pneumococcal conjugate 7-valent vaccine in children. Med Mal Infect 2013; 43: 309-321
28 Azzari C, Martinon-Torres F, Schmitt HJ et al. Evolving role of 13-valent pneumococcal conjugate vaccine in clinical practice. Pediatr Infect Dis 2014; 33: 858-864
29 Ludwig E, Unal S, Bogdan M et al. Regional advisory board position statement on optimal pneumococcal vaccination in adults. Update to 2011 consensus on adult pneumococcal disease: update on optimal pneumococcal vaccination in adults. Cent Eur J Public Health 2013; 21: 233-236
30 Roca A, Bottomley C, Hill PC et al. Effect of age and vaccination with a pneumococcal conjugate vaccine on the density of pneumococcal nasopharyngeal carriage. Clin Infect Dis 2012; 55: 816-824
31 Pletz MW, Maus U, Hohlfeld JM et al. Pneumococcal vaccination: conjugated vaccine induces herd immunity and reduces antibiotic resistance. Dtsch Med Wochenschr 2008; 133: 358-362
32 Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41
33 Link-Gelles R, Taylor T, Moore MR et al. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020. Vaccine 2013; 31: 2572-2577
34 Pletz MW, Ewig S, Lange C et al. Update Pneumonie 2012. Dtsch Med Wochenschr 2012; 137: 2265-2284
35 Centers for Diease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61: 816-819
36 Sächsische Impfkommission. Empfehlungen der Sächsischen Impfkommission zur Durchführung von Schutzimpfungen im Freistaat Sachsen. Im Internet: http://www.gesunde.sachsen.de/download/lua/LUA_HM_Impfempfehlungen_E1.pdf Stand: 01.01.2014
37 Leroux-Roels G, Maes C, De Boever F et al. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I/II randomized clinical study. Vaccine
38 Mann B, Thornton J, Heath R et al. Broadly protective protein-based pneumococcal vaccine comprised of pneumolysin-toxoid-CbpA peptide recombinant fusion protein. J Infect Dis 2014; 209: 1116-1125
39 Bresee J, Hayden FG. Epidemic Influenza - Responding to the expected but unpredictable. New Engl J Med 2013; 368: 589-592
40 Metersky ML, Masterton RG, Lode H et al. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis 2012; 16: e321-e331
41 Rothberg MB, Haessler DS. Complications of seasonal and pandemic influenza. Crit Care Med 2010; 38 (Suppl. 04) e91-e97
42 Drake JW. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci USA 1993; 90: 4171-4175
43 Mertz D, Kim TH, Johnstone J et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ 2013; 347: f5061
44 Centers for Disease Control and Prevention. Persons at risk for medical complications due to influenza. Im Internet: www.cdc.gov/flu/professionals/acip/2013-summary-recommendations.htm#at-risk [Stand: 20. 08. 2013]
45 Naleway AL, Henkle EM, Ball S et al. Barriers and facilitator to influenza vaccination and vaccine coverage in a cohort of health care personnel. Am J Infect Control 2014; 42: 371-375
46 White LF, Archer B, Pagano M. Determing the dynamics of influenza transmission by age. Emerg Themes Epidemiol 2014; 11: 4
47 Ferdinands JM, Olsho LE, Agan AA et al. Effectiveness on influenza vaccine against life-threatening RT-PCR-confirmed influenza illness in US children, 2010-2012. J Infect Dis 2014; 210: 674-683
48 Tessmer A, Welte T, Schmidt-Ott R et al. Influenza vaccination is associated with reduced severity of community-acquired pneumonia. Eur Respir J 2011; 38: 147-153
49 Rhorer J, Ambrose CS, Dickinson S et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 2009; 27: 1101-1110
50 Monto AS, Ohmit SE, Petrie JG et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361: 1260-1267
51 Prutsky GJ, Domecg JP, Elraiyah T et al. Assessing the evidence: live attenuated influenza vaccine in children younger than 2 years. A systematic review. Pediatr Infect Dis J 2014; 33: e106-e115
52 Barr IG, Russell C, Besselaar TG et al. Writing Committee of the World Health Organization Consultation on Northern Hemisphere Influenza Vaccine Composition for 2013–2014. WHO recommendations for the viruses used in the 2013–2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine 2014; 32: 4713-4725
53 Jain VK, Rivera L, Zaman K et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med 2013; 369: 2481-2491
54 Kieninger D, Sheldon E, Lin WY et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. BMC Infect Dis 2013; 13: 343
55 Domachowske JB, Pankow-Culot H, Bautista M et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013; 207: 1878-1887
56 Centers for Disease Control and Prevention. CDC advisory committee recommends an influenza vaccine option for persons with egg allergy. Im Internet: www.cdc.gov/media/releases /2013/a0620-FluBlok.html ; Stand: 21.06.2013
57 Jin J. 2014 adult immunization schedule: recombinant flu vaccine expands options for people with egg allergies. JAMA 2014; 311: 893
58 Baldo V, Baldovin T, Pellegrini M et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010; 2010: 517198
59 Tsai TF. Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults. Infect Chemother 2013; 42: 159-174
60 Zimmermann RK, Lin CJ, Ross T et al. Randomized clinical trial of high-dose influenza vaccine in nursing home residents (Abstract). IDWeek. 2013: 576b Im Internet: https://idsa.confex.com/idsa/2013/webprogram/Paper43076.html [Stand: 03. 10. 2013]
61 Young F, Marra R. A systematic review of intradermal influenza vaccines. Vaccine 2011; 29: 8788-8801
62 Mannino S, Villa M, Apolone G et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012; 176: 527-533
63 De Roux A, Marx A, Burkhardt O et al. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine 2006; 24: 1537-1542
64 Eckerle I, Rosenberger KD, Zwahlen M et al. Serologic vaccination response after solid organ transplantation: a systematic review. PLoS One 2013; 8: e56974
65 Demicheli V, Jefferson T, Al-Ansary LA et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2014; 3: CD001269
66 Avery RK. Influenza vaccines in the setting of solid-organ transplantation: are they safe?. Curr Opin Infect Dis 2012; 25: 464-468
67 Persson I, Granath F, Askling J et al. Risk of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population-and registry-based cohort study with over 2 years of follow-up. J Intern Med 2014; 275: 172-190
68 Nohynek H, Jokinen J, Partinen M et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012; 7: e33536
69 Ahmed SS, Schur PH, Macdonald NE et al. Narcolepsy, 2009 A (H1N1) pandemic influenza vaccinations: What is known and unknown about the neurological disorder, the role for autoimmunity and vaccine adjuvants. J Autoimmun 2014; 50C: 1-11
70 Touma Z, Gladman DD, Urowitz MB. Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign. Curr Opin Rheumatol 2013; 25: 164-170
71 Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 2011; 258: 1197-1206
72 Kumar D, Blumberg EA, Danziger-Isakov L et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant 2011; 11: 2020-2030
73 Smith AM, Adler FR, Ribeiro RM et al. Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae. PLoS Pathog 2013; 9: e1003238
74 Kash JC, Walters KA, Davis AS et al. Lethal synergism of 2009 pandemic H1N1 influenza virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair responses. MBio 2011; 2: e00172-11
75 Plotkin SA. The pertussis problem. Clin Infect Dis 2014; 58: 830-833
76 Chiappini E, Stival A, Galli L et al. Pertussis re-emergence in the post-vaccination era. BMC Infect Dis 2013; 13: 151
77 Hellenbrand W. Keuchhusten-Erkrankungen in den neuen Bundesländern, 2002 bis 2012. Epid Bull 2014; 1: 1-11 http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2014/01/Art_01.html
78 Robert Koch Institut. Pertussis (Keuchhusten) RKI-Ratgeber für Ärzte. Im Internet: http://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Pertussis.html [Stand: 26. 06. 2013]
79 Ward JI, Cherry JD, Chang SJ et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353: 1555-1563
80 Witt MA, Arias L, Katz PH et al. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis 2013; 56: 1248-1254
81 Klein NP, Bartlett J, Fireman B et al. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 2013; 131: e1716-e1722
82 Knuf M, Zepp F, Meyer C et al. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine 2006; 24: 2043-2048
83 Clark TA, Messonnier NE, Hadler SC. Pertussis control: time for something new?. Trend Microbiol 2012; 20: 211-213
84 Thorstensson R, Trollfors B, Al-Tawil N et al. A phase I clinical study of a live attenuated Bordetella pertussis vaccine – BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PloS One 2014; 9: e83449

Impfungen in der Pneumologie[*]

Autor*innen

Impfungen in der Pneumologie^[*]